Clinical Trial Update: Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of adalimumab in patients with moderate to severely active psoriatic arthritis that inadequately responded to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Abbott | Conditions: Arthritis, Psoriatic | Phase 3 | Status: COMPLETED